- Home
- GH vs RDNT Comparison
GH vs RDNT Comparison
Compare GH & RDNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- RDNT
- Stock Information
- Founded
- GH 2011
- RDNT 1985
- Country
- GH United States
- RDNT United States
- Employees
- GH N/A
- RDNT N/A
- Industry
- GH Medical Specialities
- RDNT Medical Specialities
- Sector
- GH Health Care
- RDNT Health Care
- Exchange
- GH Nasdaq
- RDNT Nasdaq
- Market Cap
- GH 4.9B
- RDNT 5.2B
- IPO Year
- GH 2018
- RDNT 1986
- Fundamental
- Price
- GH $98.28
- RDNT $83.70
- Analyst Decision
- GH Strong Buy
- RDNT Strong Buy
- Analyst Count
- GH 22
- RDNT 5
- Target Price
- GH $74.32
- RDNT $76.80
- AVG Volume (30 Days)
- GH 3.4M
- RDNT 715.3K
- Earning Date
- GH 10-29-2025
- RDNT 11-09-2025
- Dividend Yield
- GH N/A
- RDNT N/A
- EPS Growth
- GH N/A
- RDNT N/A
- EPS
- GH N/A
- RDNT N/A
- Revenue
- GH $902,569,000.00
- RDNT $1,969,599,000.00
- Revenue This Year
- GH $33.95
- RDNT $10.02
- Revenue Next Year
- GH $25.77
- RDNT $8.54
- P/E Ratio
- GH N/A
- RDNT N/A
- Revenue Growth
- GH 30.38
- RDNT 11.09
- 52 Week Low
- GH $28.45
- RDNT $45.00
- 52 Week High
- GH $101.57
- RDNT $93.65
- Technical
- Relative Strength Index (RSI)
- GH 77.88
- RDNT 63.93
- Support Level
- GH $88.88
- RDNT $76.64
- Resistance Level
- GH $97.51
- RDNT $79.77
- Average True Range (ATR)
- GH 4.94
- RDNT 3.26
- MACD
- GH 1.89
- RDNT 0.04
- Stochastic Oscillator
- GH 88.05
- RDNT 89.85
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About RDNT RadNet Inc.
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.